Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

<p>Abstract</p> <p>Background</p> <p>Fesoterodine is an antimuscarinic for the treatment of overactive bladder, a syndrome of urgency, with or without urgency urinary incontinence (UUI), usually with increased daytime frequency and nocturia. Our objective was to develop...

Full description

Bibliographic Details
Main Authors:	Cardozo Linda, Khullar Vik, El-Tahtawy Ahmed, Guan Zhonghong, Malhotra Bimal, Staskin David
Format:	Article
Language:	English
Published:	BMC 2010-08-01
Series:	BMC Urology
Online Access:	http://www.biomedcentral.com/1471-2490/10/14

Similar Items

Fesoterodine for the treatment of urinary incontinence and overactive bladder
by: Pamela Ellsworth
Published: (2009-11-01)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
by: Wyndaele J-J
Published: (2012-11-01)

The experience of using fesoterodine in patients with overactive bladder in the older age group
by: Elena I. Ermakova
Published: (2020-05-01)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
by: Morris V, et al.
Published: (2014-01-01)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
by: Peral C, et al.
Published: (2016-09-01)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
by: Heesakkers J, et al.
Published: (2017-10-01)

A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction
by: Bilal Chughtai, et al.
Published: (2015-03-01)

Subjective and objective response to treatment of overactive bladder: A pooled analysis of randomised controlled trials of fesoterodine in patients of >65 years
by: A. Wagg, et al.
Published: (2020-07-01)

Corrigendum to “A pilot study of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction” [Urol Sci (2015) 38–40]
by: Bilal Chughtai, et al.
Published: (2015-06-01)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
by: Castro-Diaz David, et al.
Published: (2012-07-01)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
by: Creanga Dana, et al.
Published: (2009-07-01)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model.
by: Xavier Biardeau, et al.
Published: (2017-01-01)

The overactive bladder
by: Richard Foon, et al.
Published: (2010-08-01)

Overactive bladder
by: Anna Zwierzyńska
Published: (2021-07-01)

OVERACTIVE BLADDER SYNDROME IN CHILDREN
by: E.L. Vishnevskiy
Published: (2007-03-01)

OVERACTIVE BLADDER SYNDROME IN CHILDREN
by: E.L. Vishnevskiy
Published: (2007-01-01)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder
by: Araklitis G, et al.
Published: (2020-08-01)

The Relationship between Overweight and Overactive Bladder Symptoms
by: Magdaléna Hagovska, et al.
Published: (2020-05-01)

Overactive Bladder in Children
by: Rhaiana Gondim Oliveira, et al.
Published: (2018-06-01)

Overactive bladder in males
by: Alex Gomelsky, et al.
Published: (2009-10-01)

Postmenopausal overactive bladder
by: Jacek Tomaszewski
Published: (2014-12-01)

The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment
by: Eric Chieh-Lung Chou, et al.
Published: (2014-08-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Studies of relationships between overactive bladder and frailty in the elderly
by: M. Yoshida, et al.
Published: (2020-07-01)

The relationship between overactive bladder and sexual activity in women
by: Patel Ankur S., et al.
Published: (2006-01-01)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
by: Sheng-Mou Hsiao, et al.
Published: (2019-03-01)

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics
by: Maximiliano S. Sangoi, et al.
Published: (2015-04-01)

Update on the management of overactive bladder
by: Christina Fontaine, et al.
Published: (2021-08-01)

Over Overactive Bladder (OAB)
by: Bansithi Chayaprasithi
Published: (2007-09-01)

Urinary biomarkers of overactive bladder
by: Xiao-Jun Tian, et al.
Published: (2019-05-01)

Overactive bladder - pharmacological treatment
by: Carlos Alberto Ricetto Sacomani, et al.
Published: (2019-05-01)

The Experimental overactive bladder modelling
by: O. I. Iatsyna, et al.
Published: (2018-07-01)

Review of the epidemiology of overactive bladder
by: Eapen RS, et al.
Published: (2016-06-01)

Medical management of overactive bladder
by: Sarvpreet S Ubee, et al.
Published: (2010-01-01)

Overactive bladder in the vulnerable elderly
by: Wolff GF, et al.
Published: (2014-10-01)

Overactive bladder: pharmacological treatment
by: José Carlos Truzzi, et al.

Pharmacologic management of overactive bladder
by: Sum Lam, et al.
Published: (2007-10-01)

The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder
by: Ganesh Thiagamoorthy, et al.
Published: (2016-02-01)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
by: Stacey Tannenbaum, et al.
Published: (2020-12-01)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
by: Christopher R. Chapple, et al.
Published: (2016-12-01)